CME: Ulcerative Colitis: Updates from the DDW 2019 Annual Meeting
Cost: FreeView Offer chevron_right
IBD is a broad term that includes many different forms of inflammatory bowel conditions, the most common of which are ulcerative colitis (UC) and Crohn’s disease, the former of which exclusively affects the colon and rectum. Guidelines exist for the treatment of UC, but they are constantly changing to include updated information. Despite the plethora of guidelines available, there are issues surrounding guideline adherence by physicians, patient satisfaction, the quality of treatment and a patient’s QOL. Given the data from multiple studies that physicians are either not aware of updated practice guidelines or are not utilizing them, that this lack of knowledge is affecting patient satisfaction, and that there may be demographically-based barriers to care, educational activities are warranted to keep HCPs abreast of best practices in patients with UC. This activity has been designed to review treatment strategies, emerging therapies, and gaps in care of patients with UC.
By the end of the session the participant will be able to:
- Describe long-term outcomes of UC patients with dysplasia who undergo endoscopic resection and surveillance and apply that information to a patient case
- Describe the effect of endoscopic and histologic remission as treatment targets
- Describe the risk of biologic therapy use in special populations, such as elderly and surgical patients and apply that information to a patient case
- Recall emerging data on biologic drug safety and efficacy
Healthcare professionals specializing in: gastroenterology, internal medicine, and those who otherwise commonly care for patients with UC.